查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594657

眼科藥品市場：依配藥類型、疾病、產品類型、劑型、分佈分類 - 全球預測 2025-2030

Ophthalmic Drugs Market by Dispense Type (Over the Counter, Prescription), Disease Condition (Allergy, Dry Eye Disorder, Glaucoma), Products, Dosage Form, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年眼科藥品市場價值為289.9億美元，預計到2024年將達到305.6億美元，複合年成長率為5.86%，到2030年達到432.1億美元。

由於360iResearch的市場研究分析師專注於眼科藥物，本次研究的範圍涵蓋了用於治療多種眼科疾病的藥物，包括青光眼、乾眼症、視網膜疾病和感染疾病。這些藥物有多種形式，包括眼藥水、藥膏和口服錠劑，旨在解決影響眼睛解剖和功能的疾病。由於人口老化、看螢幕時間增加以及眼睛健康意識增強，眼科疾病盛行率不斷上升，推動了對眼科藥物的需求。這些藥物在醫院藥房、零售藥房和線上管道中至關重要，因為它們的多種用途既可用於治療又可用於預防。市場成長主要是由藥物輸送系統的技術進步、對微創治療的需求不斷成長以及主要企業之間擴大產品系列的策略聯盟所推動的。

主要市場統計
基準年[2023] 289.9億美元
預測年份 [2024] 305.6億美元
預測年份 [2030] 432.1億美元
複合年成長率（%） 5.86%

最新的機會在於個人化醫療的發展，即利用基因組學根據個別患者的情況量身定做治療方案，以及緩釋性藥物輸送系統的創新，以提高患者的依從性和療效。公司可以透過進入醫療保健基礎設施不斷擴張的亞太地區等新興市場來發現巨大的成長潛力。然而，嚴格的監管障礙和先進治療的高成本可能會造成進入障礙並抑制新藥物核准。他們也面臨假藥影響品牌信譽的挑戰。

創新應著重於基因療法和生技藥品的突破，為治療以前無法治療的疾病提供新途徑。加速探索眼科微生物組與全身性疾病之間關係的研發工作可能會開闢新的治療前沿。眼科藥品市場本質上是動態的，具有緩慢到快速的成長軌跡，並強調透過品質和患者結果實現差異化。了解以患者為中心的需求並相應地最佳化產品平臺對於確保在不斷變化的環境中實現持續的業務成長和競爭優勢至關重要。

市場動態：揭示快速發展的眼科藥品市場的關鍵市場洞察

供需的動態交互作用正在改變眼科藥品市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 眼科疾病和適應症的興起
    • 擴大眼科疾病聯合治療的開發
    • 提高認知、獲得治療的機會和藥物的供應
  • 市場限制因素
    • 開發成本高，研發時間長
  • 市場機會
    • 供應商增加投資和研發活動以開發新的眼科藥物
    • 眼科生技藥品的巨大潛力
  • 市場挑戰
    • 眼科藥物的副作用不受監控

波特五力：駕馭眼科藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解眼科藥品市場的外部影響

外部宏觀環境因素在塑造眼科藥品市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解眼科藥品市場競爭狀況

眼科藥品市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣眼科藥物市場供應商的績效評估

FPNV 定位矩陣是評估眼科藥品市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為眼科藥物市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對眼科藥品市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球眼科疾病和適應症的盛行率不斷上升
      • 眼科治療聯合治療的發展取得進展

障礙

      • 提高意識、獲得治療的機會和藥物的供應
    • 抑制因素
      • 眼科藥物的開發成本高、研發耗時。
    • 機會
      • 供應商增加對眼科藥品新開發的投資和研發活動
      • 眼科生技藥品的巨大潛力
    • 任務
      • 眼科藥物的副作用不受監控
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依配藥類型分類的眼科藥品市場

  • 在商店
  • 處方箋

第7章依疾病區分的眼科藥物市場

  • 過敏
  • 乾眼症
  • 青光眼
  • 視網膜疾病
    • 糖尿病視網膜病變
    • 乾老齡化黃斑部病變
    • 濕性老齡化黃斑部病變

第8章眼科藥品市場：依產品

  • 膠囊和片劑
  • 降低
  • 凝膠
  • 軟膏
  • 解決方案和暫停

第9章按劑型分類的眼科藥物市場

  • 液體眼藥水
  • 多室給藥系統
  • 半固態眼藥水
  • 固態眼藥水

第10章 眼科藥品市場經銷商

  • 藥局
  • 醫院藥房
  • 網路藥房

第11章美洲眼科藥品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區眼科藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲眼科藥品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 博士倫計劃收購 XIIDRA
    • FDA核准NovaricCyclosporine眼藥水用於治療乾眼症
    • Eyenovia 與 Formosa 合作開發新型眼科治療藥物
    • Rivana 融資 1,200 萬美元用於開發緩釋眼內植入
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alcon Vision LLC
  • Allergan PLC by AbbVie Inc.
  • Apotex Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Carl Zeiss AG
  • Coherus Biosciences, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • Eyevensys
  • Genentech, Inc.
  • Johnson & Johnson Service, Inc.
  • Kodiak Sciences Inc.
  • Lupin Limited
  • Merck & Co.
  • Nicox SA
  • Novaliq GmbH
  • Novartis AG
  • Ocular Therapeutix, Inc.
  • OCuSOFT Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Somerset Pharma, LLC.
  • Sun Pharmaceutical Industries, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-036C5CF3A8ED

The Ophthalmic Drugs Market was valued at USD 28.99 billion in 2023, expected to reach USD 30.56 billion in 2024, and is projected to grow at a CAGR of 5.86%, to USD 43.21 billion by 2030.

As a Market Research Analyst focusing on Ophthalmic Drugs at 360iResearch, the scope of the study encompasses drugs used to treat various eye disorders, including glaucoma, dry eye syndrome, retinal disorders, and infections. These drugs come in multiple forms such as eye drops, ointments, and oral tablets aimed at addressing diseases affecting the eye's anatomy and functionality. The necessity for ophthalmic drugs is driven by the rising prevalence of eye conditions due to the aging population, increased screen time, and growing awareness about eye health. Various applications apply to both therapeutic and preventive care, making these drugs crucial across hospital pharmacies, retail pharmacies, and online channels. Market growth is significantly influenced by technological advancements in drug delivery systems, the increasing demand for minimally invasive treatments, and strategic partnerships among key players to expand product portfolios.

KEY MARKET STATISTICS
Base Year [2023] USD 28.99 billion
Estimated Year [2024] USD 30.56 billion
Forecast Year [2030] USD 43.21 billion
CAGR (%) 5.86%

Latest opportunities reside in the development of personalized medicine, which harnesses genomics to tailor treatments specific to individual patient profiles, and innovations in sustained-release drug delivery systems that enhance patient adherence and efficacy. Companies can tap into emerging markets like Asia-Pacific, where expanding healthcare infrastructure presents notable growth potential. However, stringent regulatory hurdles and the high cost of advanced therapies pose barriers to entry and can curtail new drug approvals. The market also faces challenges with counterfeit drugs impacting brand integrity.

Innovation should focus on breakthroughs in gene therapy and biologics that offer new pathways for treating previously untreatable conditions. Accelerated R&D efforts in exploring the ocular microbiome and its correlations with systemic diseases could open new therapeutic frontiers. The ophthalmic drug market exemplifies a dynamic nature, with a moderate to fast-growth trajectory and a strong emphasis on differentiation through quality and patient outcomes. Understanding patient-centric needs and optimizing product pipelines accordingly will be pivotal for sustained business growth and competitive advantage in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Ophthalmic Drugs Market

The Ophthalmic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of ophthalmic disorders and indications globally
    • Growing development combination therapies for the treatment of ophthalmic disorders
    • Increased awareness, treatment accessibility and drug availability
  • Market Restraints
    • High development costs and time taking research and development of ophthalmic drugs
  • Market Opportunities
    • Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
    • Significant potential in ophthalmic biologics
  • Market Challenges
    • Unmonitored side effects of ophthalmic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Ophthalmic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Ophthalmic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Ophthalmic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Ophthalmic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Ophthalmic Drugs Market

A detailed market share analysis in the Ophthalmic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Ophthalmic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Ophthalmic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Ophthalmic Drugs Market

A strategic analysis of the Ophthalmic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Ophthalmic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alcon Vision LLC, Allergan PLC by AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., Bayer AG, Carl Zeiss AG, Coherus Biosciences, Inc., EyePoint Pharmaceuticals, Inc., Eyevensys, Genentech, Inc., Johnson & Johnson Service, Inc., Kodiak Sciences Inc., Lupin Limited, Merck & Co., Nicox SA, Novaliq GmbH, Novartis AG, Ocular Therapeutix, Inc., OCuSOFT Inc., Pfizer Inc., Recipharm AB, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., Somerset Pharma, LLC., Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Ophthalmic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dispense Type, market is studied across Over the Counter and Prescription.
  • Based on Disease Condition, market is studied across Allergy, Dry Eye Disorder, Glaucoma, and Retinal Disorder. The Retinal Disorder is further studied across Diabetic Retinopathy, Dry Age-related Macular Degeneration, and Wet Age-related Macular Degeneration.
  • Based on Products, market is studied across Capsules & Tablets, Drops, Gels, Ointments, and Solutions & Suspensions.
  • Based on Dosage Form, market is studied across Liquid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Semisolid Ophthalmic Drug Forms, and Solid Ophthalmic Drug Forms.
  • Based on Distribution, market is studied across Drug Stores, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of ophthalmic disorders and indications globally
      • 5.1.1.2. Growing development combination therapies for the treatment of ophthalmic

disorders

      • 5.1.1.3. Increased awareness, treatment accessibility and drug availability
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and time taking research and development of ophthalmic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment and R&D activities by vendors to develop novel ophthalmic drugs
      • 5.1.3.2. Significant potential in ophthalmic biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Unmonitored side effects of ophthalmic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Ophthalmic Drugs Market, by Dispense Type

  • 6.1. Introduction
  • 6.2. Over the Counter
  • 6.3. Prescription

7. Ophthalmic Drugs Market, by Disease Condition

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Dry Eye Disorder
  • 7.4. Glaucoma
  • 7.5. Retinal Disorder
    • 7.5.1. Diabetic Retinopathy
    • 7.5.2. Dry Age-related Macular Degeneration
    • 7.5.3. Wet Age-related Macular Degeneration

8. Ophthalmic Drugs Market, by Products

  • 8.1. Introduction
  • 8.2. Capsules & Tablets
  • 8.3. Drops
  • 8.4. Gels
  • 8.5. Ointments
  • 8.6. Solutions & Suspensions

9. Ophthalmic Drugs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Liquid Ophthalmic Drug Forms
  • 9.3. Multicompartment Drug Delivery Systems
  • 9.4. Semisolid Ophthalmic Drug Forms
  • 9.5. Solid Ophthalmic Drug Forms

10. Ophthalmic Drugs Market, by Distribution

  • 10.1. Introduction
  • 10.2. Drug Stores
  • 10.3. Hospital Pharmacies
  • 10.4. Online Pharmacies

11. Americas Ophthalmic Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Ophthalmic Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Ophthalmic Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bausch + Lomb Plans to Acquire XIIDRA
    • 14.3.2. FDA Approves Novaliq's Cyclosporine Ophthalmic Solution For Treatment Of Dry Eye Disease
    • 14.3.3. Eyenovia and Formosa Partner For New Ophthalmic Therapeutics
    • 14.3.4. Re-Vana Reels in USD 12M To Develop Sustained-Release Eye Implants
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alcon Vision LLC
  • 3. Allergan PLC by AbbVie Inc.
  • 4. Apotex Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Bayer AG
  • 7. Carl Zeiss AG
  • 8. Coherus Biosciences, Inc.
  • 9. EyePoint Pharmaceuticals, Inc.
  • 10. Eyevensys
  • 11. Genentech, Inc.
  • 12. Johnson & Johnson Service, Inc.
  • 13. Kodiak Sciences Inc.
  • 14. Lupin Limited
  • 15. Merck & Co.
  • 16. Nicox SA
  • 17. Novaliq GmbH
  • 18. Novartis AG
  • 19. Ocular Therapeutix, Inc.
  • 20. OCuSOFT Inc.
  • 21. Pfizer Inc.
  • 22. Recipharm AB
  • 23. Regeneron Pharmaceuticals, Inc.
  • 24. Santen Pharmaceutical Co., Ltd.
  • 25. Senju Pharmaceutical Co., Ltd.
  • 26. Somerset Pharma, LLC.
  • 27. Sun Pharmaceutical Industries, Inc.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Teva Pharmaceutical Industries Ltd.
  • 30. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. OPHTHALMIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OPHTHALMIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPHTHALMIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPHTHALMIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY EYE DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY CAPSULES & TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY LIQUID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SEMISOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY SOLID OPHTHALMIC DRUG FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL OPHTHALMIC DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISPENSE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY RETINAL DISORDER, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM OPHTHALMIC DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 284. OPHTHALMIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. OPHTHALMIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023